PT3188727T - Tasimelteon para o tratamento da síndrome de smithmagenis - Google Patents

Tasimelteon para o tratamento da síndrome de smithmagenis

Info

Publication number
PT3188727T
PT3188727T PT157662743T PT15766274T PT3188727T PT 3188727 T PT3188727 T PT 3188727T PT 157662743 T PT157662743 T PT 157662743T PT 15766274 T PT15766274 T PT 15766274T PT 3188727 T PT3188727 T PT 3188727T
Authority
PT
Portugal
Prior art keywords
tasimelteon
magenis syndrome
smith
treating
treating smith
Prior art date
Application number
PT157662743T
Other languages
English (en)
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of PT3188727T publication Critical patent/PT3188727T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electric Connection Of Electric Components To Printed Circuits (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Processing Of Solid Wastes (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Coils Or Transformers For Communication (AREA)
  • Saccharide Compounds (AREA)
PT157662743T 2014-09-02 2015-08-29 Tasimelteon para o tratamento da síndrome de smithmagenis PT3188727T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462044856P 2014-09-02 2014-09-02
US201562169635P 2015-06-02 2015-06-02

Publications (1)

Publication Number Publication Date
PT3188727T true PT3188727T (pt) 2023-01-30

Family

ID=54147267

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157662743T PT3188727T (pt) 2014-09-02 2015-08-29 Tasimelteon para o tratamento da síndrome de smithmagenis

Country Status (17)

Country Link
US (5) US10179119B2 (pt)
EP (2) EP3188727B1 (pt)
JP (3) JP6903571B2 (pt)
KR (2) KR20240015729A (pt)
CN (2) CN116098887A (pt)
AU (2) AU2015312252B2 (pt)
BR (1) BR112017003644A2 (pt)
CA (2) CA2957588C (pt)
DK (1) DK3188727T3 (pt)
ES (1) ES2936833T3 (pt)
FI (1) FI3188727T3 (pt)
HR (1) HRP20230070T1 (pt)
HU (1) HUE061051T2 (pt)
MX (1) MX2017002796A (pt)
PT (1) PT3188727T (pt)
SI (1) SI3188727T1 (pt)
WO (1) WO2016036619A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017003644A2 (pt) * 2014-09-02 2017-11-28 Vanda Pharmaceuticals Inc métodos de tratamento de distúrbios do sono e para regular produção de melatonina.
SG11202007642RA (en) * 2018-03-04 2020-09-29 Vanda Pharmaceuticals Inc Treatment of disorders with tasimelteon
CN113365618A (zh) * 2018-09-12 2021-09-07 万带兰制药公司 改善睡眠或睡醒后表现
KR102650321B1 (ko) 2019-12-13 2024-03-21 반다 파마슈티칼즈, 인코퍼레이티드. 액체 타시멜테온 제형 및 이의 사용 방법
JPWO2022044826A1 (pt) 2020-08-27 2022-03-03
CA3229930A1 (en) * 2021-09-14 2023-03-23 Mihael Polymeropoulos Treatment of sleep disturbances in autism spectrum disorder patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2230626T3 (es) 1996-12-10 2005-05-01 Bristol-Myers Squibb Company Agentes melatonergicos de benzodioxol, benzofurano, dihidrobenzofurano y benzodioxano.
US20050137247A1 (en) 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
US7754902B2 (en) 2006-05-18 2010-07-13 Vanda Pharmaceuticals, Inc. Ruthenium(II) catalysts for use in stereoselective cyclopropanations
PT2028937E (pt) 2006-05-22 2015-04-09 Vanda Pharmaceuticals Inc Tratamento por agonista de melatonina
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
KR100928515B1 (ko) 2008-04-02 2009-11-26 주식회사 동부하이텍 데이터 수신 장치
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
WO2013112951A2 (en) 2012-01-26 2013-08-01 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CN102675268A (zh) * 2012-05-18 2012-09-19 济南志合医药科技有限公司 制备(1r,2r)-2-(2,3-二氢苯并呋喃-4-基)环丙甲胺的方法
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
BR112017003644A2 (pt) * 2014-09-02 2017-11-28 Vanda Pharmaceuticals Inc métodos de tratamento de distúrbios do sono e para regular produção de melatonina.
KR102650321B1 (ko) * 2019-12-13 2024-03-21 반다 파마슈티칼즈, 인코퍼레이티드. 액체 타시멜테온 제형 및 이의 사용 방법

Also Published As

Publication number Publication date
CA2957588A1 (en) 2016-03-10
HRP20230070T1 (hr) 2023-03-17
KR20170048541A (ko) 2017-05-08
SI3188727T1 (sl) 2023-03-31
DK3188727T3 (da) 2023-02-06
CN116098887A (zh) 2023-05-12
US10653665B2 (en) 2020-05-19
US11266622B2 (en) 2022-03-08
EP3188727A1 (en) 2017-07-12
JP7252390B2 (ja) 2023-04-04
ES2936833T3 (es) 2023-03-22
AU2020239640B2 (en) 2020-11-05
US20240293355A1 (en) 2024-09-05
JP2017526693A (ja) 2017-09-14
JP6903571B2 (ja) 2021-07-14
AU2020239640A1 (en) 2020-10-15
US20200237712A1 (en) 2020-07-30
BR112017003644A2 (pt) 2017-11-28
CA2957588C (en) 2021-08-31
US20170239210A1 (en) 2017-08-24
AU2015312252A1 (en) 2017-03-30
NZ765911A (en) 2023-08-25
JP2020143159A (ja) 2020-09-10
KR20240015729A (ko) 2024-02-05
JP2022078291A (ja) 2022-05-24
FI3188727T3 (fi) 2023-02-20
CA3124872A1 (en) 2016-03-10
US20190105297A1 (en) 2019-04-11
US20220133681A1 (en) 2022-05-05
AU2015312252B2 (en) 2020-07-02
HUE061051T2 (hu) 2023-05-28
JP7132277B2 (ja) 2022-09-06
MX2017002796A (es) 2017-06-09
WO2016036619A1 (en) 2016-03-10
EP3188727B1 (en) 2022-11-09
US10179119B2 (en) 2019-01-15
EP4137129A1 (en) 2023-02-22
NZ729901A (en) 2020-09-25
CN106604726A (zh) 2017-04-26

Similar Documents

Publication Publication Date Title
HK1245804A1 (zh) 用於治療pvns的抗csf1r抗體
HK1244217A1 (zh) 用於治療蛋白質病的方法
HK1243954A1 (zh) 用於治療患有普拉德-威利綜合征或史密斯-馬吉利綜合征的受試者的方法
GB201405800D0 (en) Process
GB201404468D0 (en) Process
GB201405210D0 (en) Process
GB201406890D0 (en) Process
IL249475A0 (en) Methods for treating itching
HUE061051T2 (hu) Tasimelteon Smith-Magenis szindróma kezelésére
GB201402950D0 (en) Process
PL3186013T3 (pl) Urządzenie do obróbki przedmiotów
GB201409126D0 (en) Process
GB201402782D0 (en) Process
GB201400137D0 (en) Process
GB201411627D0 (en) Process
SG11201703217PA (en) Engaging apparatus
EP3148525C0 (en) CAFESTOL FOR TREATING DIABETES
GB201412406D0 (en) Process
GB201405209D0 (en) Process
GB201411623D0 (en) Process
GB201410174D0 (en) Process
GB201405929D0 (en) Process
GB201403057D0 (en) Process
IL249616A0 (en) Methods for treating inflammation
PL3113919T3 (pl) Sposób powlekania fragmentu powierzchni